Share this article

Avid Bioservices has entered a partnership with the California Institute for Regenerative Medicine (CIRM) to support the manufacture of adeno-associated adenovirus (AAV) and other cell and gene therapy (CGT) programmes. 

Avid became part of the Industry Resource Partner Programme of CIRM and will offer its development and CGMP manufacturing services for programmes funded by CIRM. 

The company also plans to provide its contract development and manufacturing service suite to facilitate CIRM’s partners in the development and production of gene therapies.

These services comprise process and analytical development, virus banking, cell banking, production of drugs and fill-finish works. 

The CIRM-funded programmes will gain access to Avid’s services to cut down the time needed to advance to the clinic. 

The parties intend to carry out all the collaboration-linked works at Avid’s CGT CGMP manufacturing facility in Orange County, California, US. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

CIRM recently received $5.5bn from the state of California to provide transformative regenerative medicines on an equitable basis there and across the globe.

Avid Bioservices viral technologies general manager Drew Brennan stated: “CIRM was established with a mission to provide treatments to patients with unmet medical needs through the promise of cell and gene therapy. 

“As a proud California-based company, Avid Bioservices is excited to be collaborating with CIRM to help fulfil this vision through our strong development capabilities, established quality systems and proven commercial manufacturing experience to deliver these treatments to patients in need.”

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.